Translate Bio Announces Pricing of Initial Public Offering
Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million, before deducting underwriting discounts and commissions and expenses payable by Translate Bio.
Printed from https://innovationblog.partners.org/translate-bio-announces-pricing-of-initial-public-offering · Published 07 Nov 2018
© PARTNERS HEALTHCARE. ALL RIGHTS RESERVED